New drug cocktail aims to shrink head and neck tumors before surgery

This study tests whether a combination of drugs (pembrolizumab and N-803, with or without special immune cells called PD-L1 t-haNK cells) can help shrink head and neck cancers before surgery. About 40 adults with untreated, HPV-negative head and neck cancer will receive these treatments before their planned tumor removal. The goal is to see if the immune system can be boosted to fight the cancer more effectively.